基于中国医疗机构药品评价与遴选快速指南(第二版)的超短效胰岛素类似物多维度量化评价

Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions(the second edition)

目的对门冬胰岛素(诺和锐)、赖脯胰岛素(优泌乐)和谷赖胰岛素(艾倍得)3种超短效胰岛素类似物进行多维度量化评价,为医疗机构遴选该类药品提供参考。方法采用中国医疗机构药品评价与遴选快速指南(第二版)推荐的方法,评价3种超短效胰岛素类似物的药学特性、有效性、安全性、经济性及其他属性。结果门冬胰岛素(诺和锐)、赖脯胰岛素(优泌乐)和谷赖胰岛素(艾倍得)的总评分分别为73.5分、80.4分和70.9分。赖脯胰岛素(优泌乐)评分最高,在有效性和经济性两个维度的评分占突出优势;谷赖胰岛素(艾倍得)评分最低,在有效性和安全性两个维度的评分低于其他2种超短效胰岛素类似物。结论医疗机构在遴选超短效胰岛素类似物时,可选择门冬胰岛素(诺和锐)、赖脯胰岛素(优泌乐)和谷赖胰岛素(艾倍得)中的一种或多种,三者均为强推荐,其中优先选择总评分最高的赖脯胰岛素(优泌乐)。

Objective This study aims to conduct a multi-dimensional quantitative evaluation of three rapidacting insulin analogues,aspart(Novolog),lispro(Humalog),and glulisine(Apidra)to provide references for the selection of these drugs in medical institutions.Methods The recommended methods from the"Quick guideline for drug evaluation and selection in Chinese medical institutions(the second edition)"were employed to evaluate the pharmaceutical characteristics,effectiveness,safety,cost-effectiveness,and other attributes of the three rapid-acting insulin analogues.Results The total scores of insulins aspart(Novolog),lispro(Humalog),and glulisine(Apidra)were73.5,80.4,and 70.9,respectively.Insulin lispro(Humalog)had the highest score,demonstrating a prominent advantage in both effectiveness and cost-effectiveness dimensions.Conversely,insulin glulisine(Apidra)had the lowest score,with ratings in effectiveness and safety dimensions lower than those of the other two rapid-acting insulin analogs.Conclusion When selecting rapid-acting insulin analogs,healthcare institutions can choose one or more insulins,aspart(Novolog),lispro(Humalog),or glulisine(Apidra),all of which are strongly recommended,with priority given to insulin lispro(Humalog),which has the highest total score.